Literature DB >> 10467218

Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project.

J D Swales1.   

Abstract

Hypertension is one of the major treatable factors contributing to the burden of disease worldwide. However, despite national programs to encourage detection and treatment, there are still shortcomings in hypertension management. A large proportion of these can be attributed to socioeconomic factors, professional shortcomings, and patient noncompliance with management regimens. The Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global (EISBERG) project was conceived to examine the reasons for suboptimal management of hypertension in more detail. Emphasis was placed on control of elevated systolic blood pressure because this is often neglected despite evidence that it is more important than diastolic pressure in predicting cardiovascular risk. The goals of the project include analysis of the relative importance of systolic and diastolic blood pressure as cardiovascular risk factors, identification of any necessary changes in practice, and the development and implementation of programs to promote appropriate changes in practice or attitudes. The three components of the initiative are a formal collection of epidemiologic evidence to examine the relation between systolic blood pressure and outcome; a cross-sectional, quantitative database (CardioMonitor) providing information on the treatment of patients with cardiovascular diseases including hypertension in seven countries, and qualitative research into hypertension management to assess attitudes, awareness, and knowledge among primary care physicians, patients and their carers. The study showed more effort was directed toward control of diastolic than systolic blood pressure. Adequate control of systolic blood pressure was seldom achieved. Blood pressure targets tended to be raised in elderly patients in conflict with recommendations and evidence that there is greater benefit in treating hypertension more aggressively in this population. Despite awareness of guidelines for treating hypertension, doctors were unsuccessful in practice.

Entities:  

Mesh:

Year:  1999        PMID: 10467218     DOI: 10.1016/s0002-8703(99)70315-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

1.  The role of religion in relation to blood pressure control among a Southern California Thai population with hypertension.

Authors:  Supaporn Naewbood; Siroj Sorajjakool; Somporn Kantharadussadee Triamchaisri
Journal:  J Relig Health       Date:  2012-03

2.  Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension.

Authors:  Yves Lacourcière; Luc Poirier; Jean Lefebvre; Stuart A Ross; Frans H Leenen
Journal:  Can J Cardiol       Date:  2010-10       Impact factor: 5.223

Review 3.  Fixed low-dose combination therapy for hypertension.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

4.  Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.

Authors:  Massimo Volpe; Peter Brommer; Uwe Haag; Cristina Miele
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

5.  The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988--1994.

Authors:  J L Whyte; P Lapuerta; G J L'Italien; S S Franklin
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Jul-Aug       Impact factor: 3.738

6.  Physician practice patterns in the treatment of isolated systolic hypertension in a primary care setting.

Authors:  Jeff Borenstein; Joanna L Whyte; Enkhe Badamgarav; Delia Vogel; Stephen Deutsch; Scott Weingarten; Pablo Lapuerta
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Mar-Apr       Impact factor: 3.738

7.  Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

Authors:  Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

8.  Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.

Authors:  Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

Review 9.  Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.

Authors:  Mark Greathouse
Journal:  Vasc Health Risk Manag       Date:  2006

Review 10.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.